Connecting for innovation and equity in global health
- This event has passed.
Pandemic Preparedness and Response Conversation Series
February 1 @ 8:00 am - 5:00 pm
About the event
Unbiased metagenomics hold considerable promise in our ability to rapidly detect and respond to emerging infectious disease threats. The scientists at the Chan Zuckerberg (CZ) Biohub and UCSF are working to improve scale and access to next- generation sequencing tools around the globe. Two colleagues from CZ Biohub and UCSF will join Alliance member UCSF to talk about their work.
Speakers:
Cristina M. Tato, PhD, M.PH, Director of Rapid Response, CZ Biohub
Cristina Tato received a Ph.D. in immunology from the University of Pennsylvania, where she studied transcription factor families and their downstream signaling pathways. As a postdoctoral fellow (NIH and Schering-Plough Biopharma), she continued using in vivo models of infection and autoimmune inflammation to gain insight into how these transcription factors mediate host resistance to infection, regulate the production of inflammatory cytokines, and affect the development of innate and adaptive immunity. At Stanford’s Institute for Immunity, Transplantation and Infection, Tato focused on the tactical application of systems immunology methods for studying human health and disease and for evaluating vaccine efficacy. She leads the Rapid Response Team at CZ Biohub, which plans and implements activities to strengthen global emergency response efforts to epidemics.
Chaz Langelier, MD, PhD, UCSF Department of Medicine, Division of Infectious Diseases
The translational research in my lab bridges basic and clinical investigation by engaging genomic technologies to understand relationships between microbes, host response and clinical outcomes. We study lower respiratory tract infections, ARDS, sepsis, nosocomial infections, and emerging pathogens including SARS-CoV-2. One focus area involves developing new diagnostic techniques that combine metagenomic sequencing and machine learning to simultaneously profile both host and microbiome from clinical samples. A second focus area involves studying the host response to infections and identifying disease sub-phenotypes that correlate with outcomes. Genomic epidemiology is a third focus area, and our group carries out real-time assessment of hospital outbreaks and surveillance for emerging respiratory pathogens.